Fresenius Delayed By FDA Inspection Uncertainty As It Works Towards US Pegfilgrastim Launch

“Pegfilgrastim is not just another launch, this is our entry into the US biosimilars market,” stated Ali Ahmed, senior vice president of US biosimilars at Fresenius Kabi, talking about the company’s plan to launch its proposed Neulasta biosimilar in the US. In an exclusive interview, Ahmed told Generics Bulletin that “we engaged with a lot of key stakeholders and they're very excited for Fresenius Kabi to enter into the biosimilar market in the US.”